Log in

Ipsen: new indication for its flagship product in the United States

The French pharmaceutical group Ipsen announced Monday that the US Agency for Drugs (FDA) had authorized a new oncology indication of its flagship product Somatuline, which makes the bulk of its sales in the United States.


AstraZeneca gives Aspen the rest of its rights to its anesthetics

British pharmaceutical group AstraZeneca announced on Thursday the sale to South Africa of Aspen of the remaining rights on its anesthetic drugs, for 555 million (466 million).


Sanofi / Regeneron: therapeutic breakthrough status for a treatment against skin cancer

The French pharmaceutical group Sanofi and its American partner Regeneron Pharmaceutical announced on Friday that the American Medicines Agency (FDA) has granted the status of historic breakthrough to cemiplimab, a treatment against advanced skin cancer.


Sanofi appoints new president France, Guillaume Leroy

Guillaume Leroy, 49 years, will become the new president France of Sanofi from the 1er October, replacing Philippe Luscan, announced Tuesday the French pharmaceutical giant.


Ipsen: Positive study for advanced kidney cancer treatment

Ipsen and Exelixis on Sunday unveiled results of a study showing that their treatment of advanced kidney cancer resulted in a "statistically significant improvement in progression-free survival" of the disease in patients compared to the reference treatment current.


a3p-100pxhaut logo


Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb here )

  group    administrators A3P
& Project Managers

letter   newsletter A3P